09:48 AM EST - ProMetic Life Sciences Inc. : Announced that it will be initiating a double-blind, placebo-controlled phase 2 clinical trial in patients suffering from scleroderma. ProMetic Life Sciences Inc.
shares T.PLI are trading down $0.06 at $3.11.
